Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO) take investors and analysts through the top line comparative trial results of Zelira’s diabetic nerve pain drug vs Lyrica® including efficacy, safety and next steps for the organisation.
Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.